Appeal 2007-1633
Application 09/480,236
The Examiner relies on the following prior art references to show
unpatentability:
Neville 6,103,235 Aug. 15, 2000
Kreitman, R.J., et al., Recombinant Single-Chain Immunotoxins Against T
and B Cell Leukemias, 13 Leukemia and Lymphoma 1-10 (1994).
Kussie, P.H., et al., A Single Engineered Amino Acid Substitution Changes
Antibody Fine Specificity, 152 J. Immunology 146-152 (1994).
Chen, C., et al., Enhancement and destruction of antibody function by
somatic mutation: unequal occurrence is controlled by V gene combinatorial
associations, 14(12) The EMBO J. 2784-2794 (1995).
Kreitman, R.J., et al., Targeting Pseudomonas exotoxin to hematologic
malignancies, 6 Cancer Biology 297-306 (1995).
The rejections as presented by the Examiner are as follows:
1. Claims 51-53 stand rejected under the written description provision of
35 U.S.C. § 112, first paragraph.
2. Claims 50 and 51 stand rejected under the enablement provision
35 U.S.C. § 112, first paragraph.
3. Claims 35-54 stand rejected under 35 U.S.C. § 103(a) as unpatentable
over the combination of Neville, Kreitman ’95 and Kreitman ’94.
We affirm.
DISCUSSION
Written Description:
Claims 51-53 stand rejected under the written description provision of
35 U.S.C. § 112, first paragraph. The Examiner finds that “[t]here is
insufficient written description to show that Appellant [sic] was in
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013